The kidney has another way to do this job entirely
In the long effort to understand how the human body manages its most essential functions, a Mayo Clinic nephrologist has uncovered a hidden mechanism within the kidney — one that operates entirely outside the hormonal pathway textbooks have described for generations. Using probenecid, a drug older than most living patients, Fouad Chebib and his team discovered that urate, a molecule long associated with gout, can signal kidney cells to conserve water through a pathway independent of vasopressin. For the 140,000 Americans whose kidneys are slowly consumed by polycystic kidney disease, this finding offers not just a new scientific chapter, but the possibility of a more livable life.
- Patients on tolvaptan — the only approved PKD treatment — produce up to seven liters of urine daily, waking multiple times each night in a cycle that drives many to abandon the drug entirely.
- A chance experiment with a 1940s-era medication revealed that the kidney possesses a second, previously unknown water-regulation system, upending decades of established physiology.
- Adding probenecid to tolvaptan reduced urine output by 30% in trial patients, collapsing nightly bathroom trips from several to roughly one and restoring a meaningful measure of sleep and dignity.
- Probenecid itself is too blunt an instrument — old, multi-systemic in its effects, and barely manufactured — making it a proof of concept rather than a destination.
- Researchers are now working to engineer precision therapies that target the newly mapped urate-signaling pathway directly, aiming to separate the benefit from the drug's limitations.
A nephrologist at Mayo Clinic set out to test whether an old drug might worsen polycystic kidney disease — and found it did the opposite. Fouad Chebib, whose own father developed PKD, had been studying the genetic disorder that slowly fills kidneys with fluid-filled cysts until dialysis or transplant becomes unavoidable. When his team introduced probenecid, a medication from the 1940s, into their research, it revealed something the field had not seen before.
For decades, the kidney's water-regulation system was understood through a single lens: the hormone vasopressin signals the kidney to reabsorb water and concentrate urine. Chebib's findings, published in the Journal of Clinical Investigation, describe a second pathway operating entirely independently of that hormone. The mechanism centers on urate — a molecule typically linked to gout — which acts as an internal cellular signal, triggering water channels to move to the kidney cell surface. No physiology textbook currently describes it.
The discovery carries immediate weight for PKD patients. The disease's only approved treatment, tolvaptan, slows cyst growth by blocking vasopressin — but at a steep cost. Patients produce two to three times the normal volume of urine daily, waking repeatedly through the night. Many stop taking the drug because the disruption becomes unbearable.
When probenecid was added to tolvaptan in preclinical and small clinical studies, urine volume fell by roughly 30 percent. Patients who had been waking several times nightly reported waking only once. Quality of life improved, and tolvaptan's therapeutic effect remained intact.
Probenecid, however, is not the endpoint. It affects multiple body systems and is no longer widely produced. Chebib's team views it as a key — one that opened a door to a pathway now available for more precise drug design. The work ahead involves building therapies specifically engineered for this urate-signaling mechanism, ones that could offer the same relief without the old drug's constraints. For Chebib, the science and the personal have always been intertwined, and what began as a son's response to his father's illness may yet change how millions of people live with a disease that still has no cure.
A nephrologist at Mayo Clinic stumbled onto something unexpected while testing an old drug on kidney cells in a lab. Fouad Chebib and his team were studying polycystic kidney disease—a genetic disorder where fluid-filled cysts gradually destroy kidney function—and they wanted to see if probenecid, a medication from the 1940s, would make the disease worse. It did the opposite.
For decades, medical science has understood the kidney's water-regulation system as a fairly straightforward affair: the hormone vasopressin tells the kidney to reabsorb water and concentrate urine, preventing dehydration. Chebib's discovery, published in the Journal of Clinical Investigation, reveals the kidney has another way to do this job entirely, one that works independently of vasopressin. The mechanism involves urate—a molecule usually associated with gout—which acts as a cellular signal inside kidney cells, triggering a chain of events that moves water channels to the cell surface. It's a pathway that traditional physiology textbooks don't describe.
The practical implications matter most to the roughly 140,000 Americans living with autosomal dominant polycystic kidney disease, the most common inherited form of PKD. The disease causes cysts to accumulate over years, gradually eroding kidney function until patients need dialysis or a transplant. The only approved treatment, tolvaptan, works by blocking vasopressin and does slow cyst growth. But it comes with a brutal side effect: patients produce 6 to 7 liters of urine daily—roughly three times normal output. Many wake multiple times each night to urinate. Some stop taking the drug because the burden becomes unbearable.
When Chebib's team added probenecid to the treatment regimen in preclinical studies and a small clinical trial, something shifted. Urine volume dropped by about 30 percent on average. Patients went from waking several times nightly to roughly once. They reported their quality of life improved. The drug preserved tolvaptan's therapeutic benefit while making the side effect manageable.
But probenecid itself is not the answer. It's an old medication, affects multiple body systems, and isn't widely manufactured anymore. Chebib's team sees it differently—as a key that unlocked a door. The real work ahead involves designing new drugs built specifically to target this urate-signaling pathway, therapies that could offer the same benefit without probenecid's limitations. For Chebib, the research carries personal weight. His father developed PKD, a fact that drew him to kidney science in the first place. What began as personal motivation has become something that could reshape how millions of patients live with a disease that has no cure.
Citações Notáveis
It's not every day that you uncover a new way the kidney carries out that fundamental function.— Fouad Chebib, M.D., Mayo Clinic nephrologist
The goal is to preserve the therapeutic benefit of tolvaptan while reducing its burden.— Fouad Chebib, M.D.
A Conversa do Hearth Outra perspectiva sobre a história
So you found that an old drug worked better than expected. How does that lead to understanding the kidney itself?
The drug was a window. We weren't trying to discover a new pathway—we were testing whether probenecid would make cyst growth worse. When it didn't, we had to ask why. That question led us to urate, and then to the whole mechanism.
And this mechanism exists alongside the vasopressin system that everyone's known about for decades?
Exactly. The kidney has been doing this the whole time, but we didn't see it because we weren't looking for it. It's humbling, actually—to find out a fundamental process has a backup system nobody described.
For someone with PKD on tolvaptan, what does this actually change about their day?
Right now, they're waking up five or six times a night to urinate. With probenecid added, that drops to once. They can sleep. They can leave the house without planning their life around a bathroom. The drug still works against the disease, but the person can actually live.
Why not just use probenecid long-term then?
Because it's old, it affects too many systems in the body, and it's barely made anymore. We used it to understand the pathway. Now we design something better—something that only targets what we need.
How long until patients see a new drug?
That's the honest answer I can't give yet. We know the mechanism now. The next phase is harder—making something safe and specific enough to use in people. Years, probably.